mounjaro tirzepatide patent expiration date Injection: Package Insert / Prescribing Info / MOA In weight loss battle, Novo – when does the patent on

We like the tolerability profile of that mechanism, but we are interested in building that out further. This is a clear signal to the market that their current $2.3B deal with Gubra (for an Amylin agonist) is just the foundation, and they are actively looking for additional assets, most likely a GLP-1, to create a CagriSema-like combination therapy

While GLP-1 medications are generally considered heart-healthy for many, some patients also experience a slight increase in resting heart rate when taking them

These symptoms are generally mild to moderate and transient

Zepbound vs Wegovy and Saxenda While clinical trials have demonstrated Zepbound to be the most effective GLP-1 for weight-loss yet, it's not your only option